This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Insomnia
GABAA receptor potentiators
EVT-201 GABAA receptor positive allosteric modulator
Lorediplon (GF-015535-00) GABAA receptor positive allosteric modulator
Zuranolone (SAGE-217) GABAA receptor positive allosteric modulator
Orexin receptor antagonists
Seltorexant (MIN-202, JNJ,42847922, JNJ-922) selective OX2 receptor antagonist
Vornorexant (ORN-0829, TS-142) dual OX1 and OX2 receptor antagonist
Melatonin receptor agonists
Piromelatine (Neu-P11) melatonin receptor agonist and 5-HT1A and 5-HT1D receptor agonist
Nociceptin receptor agonists
Sunobinop (IMB-115, IT-1315, S-117957, V-117957) nociceptin receptor agonist
Hypersomnia/narcolepsy
Orexin receptor agonists
Danavorexton (TAK-925) OX2 receptor-selective agonist via IV infusion
TAK-994 OX2 receptor agonist pill (orally available)
Monoaminergics
Flecainide/modafinil (THN-102) modafinil (dopamine reuptake inhibitor) and flecainide (antiarrhythmic) combination
Mazindol controlled release (NLS-1001, NLS-1) norepinephrine-predominant serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) Reboxetine (AXS-12) norepinephrine reuptake inhibitor (NRI)